

CLAIMS

1. Use of an anti-HSV antibody or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said medicament is to be topically administered and the antibody is capable of inhibiting the spreading of HSV from an infected cell to an adjacent second non-infected cell (cell-to-cell spread).
2. The use according to claim 1, wherein said anti-HSV antibody is a monoclonal or a polyclonal antibody.
3. The use according to claim 1 or claim 2, wherein said anti-HSV antibody is a humanized or fully human antibody.
4. The use according to any one of claims 1 to 3, wherein said anti-HSV antibody recognizes the glycoprotein B (gB) of the HSV-1 and/or HSV-2.
5. The use according to claim 1 or 4, wherein the antibody is capable of inhibiting cell-to-cell spread independent from antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC).
6. The use according to any one of claims 1 to 5, comprising the complementarity determining regions V_HCDR1 comprising SEQ ID NO: 1, V_HCDR2 comprising SEQ ID NO: 2, V_HCDR3 comprising SEQ ID NO: 3, V_LCDR1 comprising SEQ ID NO: 4, V_LCDR2 comprising SEQ ID NO: 5, and V_LCDR3 comprising SEQ ID NO:6.
7. The use according to claim 6, wherein the antibody comprises an amino acid sequence with at least 70 % sequence identity to the amino acid residues shown in positions 1 to 30, 38 to 51, 68 to 99, and 112 to 122 of SEQ ID NO: 7 and in positions 1 to 23, 41 to 55, 63 to 94, and 104 to 114 of SEQ ID NO: 8.
8. The use according to claim 6 or claim 7, wherein said antibody comprising the V_H of SEQ ID NO:9 and the V_L of SEQ ID NO:10.

9. The use according to any one of claims 6 to 8, wherein said antibody recognizes the same epitope as mAb 2c, wherein said epitope is located at the amino acids 172-195 and 295-313 of glycoprotein B of HSV-1 and HSV-2.
10. The use according to any one of claims 5 to 9, wherein said antibody is the mAb 2c antibody.
11. The use according to any one of claims 1 to 9, wherein said antibody is to be topically applied to infected mucosal or epidermal tissue of the lips, genitals, nose, ears, eyes, fingers, toes and/or skin areas throughout the body, preferably on the head, the jaw area, neck, chest, face, stomach and/or legs.
12. The use according to any one of claims 1 to 11, wherein said antibody is to be topically applied to areas surrounding the infected mucosal or epidermal tissue.
13. The use according to any one of claims 1 to 12, wherein said antibody is to be administered in combination with a virostatic agent.
14. The use according to claim 13, wherein said virostatic agent is selected from the group consisting of the drug classes of nucleoside analogues, pyrophosphate analogues, nucleotide analogues, an amantadin derivative, and helicase-primase inhibitors.
15. The use according to claim 14, wherein said nucleoside analogue is selected from the group consisting of Acyclovir, Penciclovir, Valacyclovir and Famaciclovir;
wherein said pyrophosphate analogue is Foscarnet;
wherein said nucleotide analogue is Cidofovir;
wherein said amantadin derivative is Tromantandin; and
wherein said helicase-primase inhibitor is Pritelivir.
16. The use according to any one of claims 1 to 15, wherein the anti-HSV antibody is a full-length antibody/complete antibody.
17. The use according to any one of claims 1 to 16, wherein the medicament is a pharmaceutical composition which further comprises at least one pharmaceutically acceptable excipient.